NANOPARTICLE ENABLED DRUG DELIVERY SYSTEMS FOR ALZHEIMER'S DISEASE ADVANCING BEYOND THE BLOOD-BRAIN BARRIER
SURYA SAGAR
Chemistry
December 2023
This study examines nanoparticle-enabled Alzheimer's drug delivery methods that cross the blood-brain barrier. The research investigates drug-loaded nanoparticles' ability to transfer therapeutic agents to the brain, addressing Alzheimer's treatment problems caused by the BBB.The approach uses hydrophilic, charged, and fluorescent markers Thioflavin-T (ThT) and D-Penicillamine with nanoparticles. Emulsion polymerization creates ThT-loaded core-shell latex particles that are stereotaxically injected into mice brains for in vivo investigations. The biodistribution of 125I-CQ BCA and nanoparticles is examined over time to determine their blood circulation and accumulation in important organs such the brain, liver, and spleen. Microemulsion precursors are used to conjugate D-Penicillamine to nanoparticles for Alzheimer's disease chelation treatment. Under different settings, nanoparticle stability and biological characteristics are examined. The study examines how D-Penicillamine prevents metal-induced beta amyloid protein precipitation and maintains amyloid beta solubility in CuCl2.Nanoparticle biodistribution patterns show their brain-reaching efficacy. Dentate gyrus ThT-loaded core-shell latex particles may be useful for Alzheimer's pathology research. D-Penicillamine-conjugated nanoparticles are stable and prospective metal-induced amyloid beta aggregation inhibitors. The undertaking looks to improve nanoparticle-based drug delivery techniques for Alzheimer's disease treatment by penetrating the blood-mind barrier. These discoveries recommend explicit treatment procedures for this neurodegenerative condition might be investigated.
© Airo Journals 2021
